TGA cracks door on filings

Posted 20 January 2021 AM

As part of its new transparency measures for prescription medicines, the TGA has begun publishing medicine applications that are under evaluation - information that has never been disclosed to the public before.

Starting this month, the regulatory body is publishing details of major innovator medicines that have been accepted and are under evaluation, excluding applications for new generic and biosimilar medicines.

To see the whole article, please login